H
Hubei Biocause Pharmaceutical Co Ltd
SZSE:000627
Hubei Biocause Pharmaceutical Co Ltd
SZSE:000627
Price:
3.93
CNY
1.55%
Market Cap:
19.4B
CNY
Balance Sheet
Balance Sheet Decomposition
Hubei Biocause Pharmaceutical Co Ltd
Hubei Biocause Pharmaceutical Co Ltd
| Cash & Short-Term Investments | 8.5B |
| Insurance Receivable | 715m |
| PP&E | 1.5B |
| Long-Term Investments | 216.4B |
| Other Assets | 58B |
Balance Sheet
Hubei Biocause Pharmaceutical Co Ltd
Hubei Biocause Pharmaceutical Co Ltd
Currency: CNY
Millions
Annual
| Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash & Cash Equivalents |
59
|
62
|
10 953
|
11 152
|
18 317
|
13 680
|
27 029
|
25 650
|
30 665
|
28 577
|
|
| Cash |
0
|
0
|
247
|
0
|
0
|
0
|
0
|
23 250
|
26 309
|
28 154
|
|
| Cash Equivalents |
59
|
62
|
10 706
|
11 152
|
18 317
|
13 680
|
27 029
|
2 399
|
4 356
|
424
|
|
| Total Receivables |
335
|
70
|
6 706
|
7 414
|
7 717
|
1 348
|
1 957
|
2 984
|
3 863
|
4 354
|
|
| Insurance Receivable |
0
|
0
|
251
|
201
|
261
|
322
|
1 545
|
772
|
936
|
1 171
|
|
| Total Current Assets |
394
|
131
|
17 659
|
18 566
|
26 035
|
15 027
|
28 986
|
28 634
|
34 528
|
32 931
|
|
| PP&E Net |
463
|
335
|
587
|
699
|
853
|
585
|
605
|
830
|
844
|
1 291
|
|
| PP&E Gross |
463
|
335
|
587
|
699
|
853
|
585
|
605
|
830
|
844
|
1 291
|
|
| Accumulated Depreciation |
404
|
475
|
588
|
646
|
661
|
51
|
68
|
138
|
216
|
260
|
|
| Intangible Assets |
504
|
490
|
549
|
520
|
213
|
109
|
190
|
270
|
299
|
283
|
|
| Goodwill |
0
|
0
|
6 186
|
6 186
|
6 186
|
6 186
|
6 192
|
6 192
|
6 192
|
6 193
|
|
| Note Receivable |
31
|
292
|
20 317
|
17 884
|
38 759
|
24 434
|
35 676
|
38 257
|
37 987
|
42 304
|
|
| Long-Term Investments |
717
|
1 161
|
72 327
|
96 360
|
105 946
|
158 610
|
166 208
|
188 948
|
207 812
|
217 763
|
|
| Other Assets |
0
|
0
|
6 186
|
6 186
|
6 186
|
6 186
|
6 192
|
6 192
|
6 192
|
6 193
|
|
| Total Assets |
2 108
N/A
|
2 409
+14%
|
117 877
+4 793%
|
140 417
+19%
|
178 254
+27%
|
205 274
+15%
|
239 403
+17%
|
263 904
+10%
|
288 599
+9%
|
301 936
+5%
|
|
| Liabilities | |||||||||||
| Insurance Policy Liabilities |
0
|
0
|
93 801
|
110 767
|
144 687
|
168 392
|
198 891
|
216 419
|
243 408
|
256 932
|
|
| Accounts Payable |
148
|
126
|
1 708
|
1 762
|
6 509
|
1 479
|
1 643
|
2 478
|
2 350
|
2 817
|
|
| Short-Term Debt |
449
|
319
|
424
|
287
|
29
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
0
|
5
|
7
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
8
|
10
|
4
|
|
| Total Current Liabilities |
597
|
445
|
2 132
|
2 053
|
6 544
|
1 479
|
1 644
|
2 486
|
2 360
|
2 821
|
|
| Long-Term Debt |
0
|
42
|
360
|
41
|
111
|
0
|
2 760
|
6 243
|
6 880
|
7 171
|
|
| Deferred Income Tax |
22
|
139
|
1 186
|
850
|
897
|
1 049
|
1 519
|
1 281
|
1 348
|
1 378
|
|
| Minority Interest |
41
|
44
|
6 596
|
7 368
|
7 022
|
13 130
|
13 453
|
14 921
|
13 191
|
13 044
|
|
| Total Liabilities |
659
N/A
|
670
+2%
|
104 075
+15 434%
|
121 080
+16%
|
159 262
+32%
|
184 051
+16%
|
218 268
+19%
|
241 351
+11%
|
267 187
+11%
|
281 346
+5%
|
|
| Equity | |||||||||||
| Common Stock |
1 354
|
1 354
|
4 259
|
4 941
|
4 941
|
4 941
|
4 941
|
4 941
|
4 941
|
4 941
|
|
| Retained Earnings |
65
|
313
|
2 050
|
3 270
|
4 399
|
6 026
|
6 112
|
6 533
|
6 783
|
5 588
|
|
| Additional Paid In Capital |
30
|
30
|
6 917
|
11 071
|
11 098
|
11 095
|
11 095
|
11 094
|
11 094
|
11 041
|
|
| Unrealized Security Profit/Loss |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
56
|
1 471
|
1 072
|
|
| Other Equity |
0
|
43
|
575
|
56
|
1 445
|
839
|
1 013
|
41
|
66
|
93
|
|
| Total Equity |
1 449
N/A
|
1 740
+20%
|
13 802
+693%
|
19 337
+40%
|
18 992
-2%
|
21 223
+12%
|
21 135
0%
|
22 553
+7%
|
21 412
-5%
|
20 590
-4%
|
|
| Total Liabilities & Equity |
2 108
N/A
|
2 409
+14%
|
117 877
+4 793%
|
140 417
+19%
|
178 254
+27%
|
205 274
+15%
|
239 403
+17%
|
263 904
+10%
|
288 599
+9%
|
301 936
+5%
|
|
| Shares Outstanding | |||||||||||
| Common Shares Outstanding |
1 354
|
1 354
|
4 259
|
4 941
|
4 941
|
4 941
|
4 941
|
4 941
|
4 941
|
4 941
|
|
Switch to:
Switch to:
See Also
Discover More
You don't have any saved screeners yet
